RxDoctor Payments Data

Amy Dorsey

Family · Wintersville, OHNPI 1194780924

Payments from drug & device makers

$3,337in general payments, 2019–2025

Across 189 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$653
  • Amgen$536
  • Novo Nordisk$439
  • Lilly USA, LLC$323
  • Xeris Pharmaceuticals, Inc.$250
  • AbbVie$158
  • plus $979 from 19 others

What the payments were for

  • Food & beverage$3,325100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,337 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$49,597
Medicare patients
226
Services billed
503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin23$22,513
OzempicSemaglutide13$21,246
Celecoxib14$1,326
CefuroximeCefuroxime Axetil28$659
Levothyroxine Sodium81$635
Omeprazole45$530
Potassium Chloride27$502
FenofibrateFenofibrate Nanocrystallized22$476
Rosuvastatin Calcium72$462
Escitalopram Oxalate21$385
Losartan Potassium64$323
Olmesartan Medoxomil16$304
Metoprolol Succinate25$279
Atorvastatin Calcium34$278
Pantoprazole Sodium35$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$149$22,51323 claims
Novo NordiskOzempic$439$21,24613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.

Other family in Wintersville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →